ClinicalTrials.gg
CompletedNCT00819039Updated Jan 26, 2021Results posted

A Study of Aprepitant (MK-0869) in Pediatric Participants Undergoing Surgery (MK-0869-148)

A Phase 1 interventional study of Aprepitant and Ondansetron in Postoperative Nausea and Vomiting, sponsored by Merck Sharp & Dohme LLC. Completed at 6 sites in 5 countries. Open to participants aged 6 Months to 17 Years. Per ClinicalTrials.gov, last updated 2021-01-26.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
98
Allocation
Randomized
Ages
6 Months to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies testing aprepitant in Postoperative Nausea and Vomiting — 2 open to participants now, 2 under way, none of them phase 3. Aprepitant · Postoperative Nausea and Vomiting.

Enrollment
18th of 27
98 · median 115
Started
2009
the only one that year
Phase 1
2 of 27
none open now
Registered
6th of 27
by date
Lead sponsor
2 of 27
Merck Sharp & Dohme LLC

Among the 27 studies testing aprepitant in Postoperative Nausea and Vomiting, this one is the 18th largest by enrollment, is the only one that started in 2009, is one of 2 in phase 1, and was the 6th registered.

Postoperative Nausea and Vomiting

638 studies on the registry are indexed under Postoperative Nausea and Vomiting; 110 are open to participants now.

Browse Postoperative Nausea and Vomiting studies →

Open to participants now

2 of the 27 studies testing aprepitant in Postoperative Nausea and Vomiting are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About aprepitant

Aprepitant: first FDA approval 2003 (EMEND), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 65 Postoperative Nausea and Vomiting studies recruiting now, 22 (34%) set no upper age limit and 37 (57%) stop at 75 or younger; 14 take children under 18; 11 take healthy volunteers.

This study: 6 Months to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing aprepitant in Postoperative Nausea and Vomiting, or all of them as a file.
02

Study summary

This two part study will determine the appropriate dosing regimen of aprepitant for the prevention of postoperative nausea and vomiting (PONV) in pediatric participants 6 months to 17 years of age, by assessing pharmacokinetic parameters and monitoring safety and tolerability of administered doses. Part I will be an open label investigation of a single dose of aprepitant measuring pharmacokinetics at specified time points up to 48 hours after aprepitant dosing. Part II will be a double blind trial of participants randomized to receive either aprepitant or ondansetron.

03

Conditions studied

  • Postoperative Nausea and Vomiting
04

Who can participate

Ages eligible
6 Months to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant is scheduled to have surgery requiring a 48 hour (Part I) or 24 hour (Part II) hospital stay
  • Participant is scheduled to receive general anesthesia
  • Participant is scheduled to receive opioids (e.g. morphine or fentanyl)
  • Female participants of must have negative pregnancy test prior to drug administration
  • A female participant who is of must agree to remain abstinent or use a barrier form of for at least 14 days prior to, throughout, and for at least one month following the last dose of study medication
  • Participant weighs 6 kg or more

Exclusion criteria

Exclusion Criteria:

  • Participant is undergoing surgery for a life-threatening condition
  • Participant is pregnant or breast feeding
  • Participant has vomited within 24 hours prior to surgery
  • Participant has a known history of or is currently taking other medicinal products that lead to QT prolongation
  • Participant has an active infection (e.g., pneumonia), congestive heart failure, bradyarrythmia, any uncontrolled disease (e.g., diabetic ketoacidosis, gastrointestinal obstruction), evidence of any respiratory, metabolic, hepatic, renal dysfunction, or a history of any illness, including morbid obesity, that might pose unwarranted risk
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
98 participants (actual)

Study arms

  • Experimental
    Part 1: Oral Aprepitant

    In Study Part 1, participants aged 6 months to 17 years received a single oral dose of aprepitant on Day 1.

    Drug: Aprepitant

  • Experimental
    Part 2: Oral Aprepitant

    In Study Part 2, participants aged 6 months to 17 years received a single oral dose of aprepitant on Day 1.

    Drug: Aprepitant

  • Active comparator
    Part 2: Intravenous Ondansetron

    In Study Part 2, participants aged 6 months to 17 years received a single intravenous dose of ondansetron on Day 1.

    Drug: Ondansetron

Interventions

  • Aprepitant administered orally or intraveously.

    Also known as: Emend

  • Ondansetron administered intravenously.

    Also known as: Zofran

06

What researchers measure

Primary outcomes

  1. Area Under the Curve From 0-48 (AUC0-48) of Aprepitant Following a Single Oral Dose in Study Part 1

    Blood samples of 0.5 mL were collected from participants for the analysis of AUC0-48 at specified time points: pre-dose, and 1, 2, 3, 4, 8, 12, 24, and 48 hours post aprepitant single dose.

    Time frame: Pre-dose, and 1, 2, 3, 4, 8, 12, 24, and 48 hours post-dose

  2. Maximum Plasma Concentration (Cmax) of Aprepitant Following a Single Oral Dose in Study Part 1

    Blood samples were collected from participants for the analysis of Cmax up to 48 hours after dosing.

    Time frame: 48 Hours Post-Dose

  3. Time to Maximum Plasma Concentration (Tmax) of Aprepitant Following a Single Oral Dose in Study Part 1

    Blood samples were collected from participants for the analysis of Tmax up to 48 hours after dosing.

    Time frame: 48 Hours Post-Dose

  4. Plasma Concentration of Aprepitant at 24 Hours (C24 hr) Following a Single Oral Dose in Study Part 1

    Blood samples were collected from participants for the analysis of C24 hr at 24 hours after dosing. N/A indicates that \>50% of measurements were below the lower level of quantitaion (LLOQ).

    Time frame: 24 Hours Post-Dose

  5. Plasma Concentration of Aprepitant at 48 Hours (C48 hr) Following a Single Oral Dose in Study Part 1

    The mean plasma concentration of aprepitant was evaluated in participants at 48 hours following a single oral dose.

    Time frame: 48 Hours Post-Dose

  6. Number of Participants Experiencing Adverse Events (AEs)

    Time frame: Up to 21 Days Post-Surgery

  7. Number of Participants Discontinuing Study Treatment Due to AEs

    Time frame: Day 1

Secondary outcomes

  1. Number of Participants With No Vomiting Up to 24 Hours Following Surgery in Study Part 2

    Time frame: Up to 24 Hours

  2. Number of Participants With Complete Response Up to 24 Hours Following Surgery in Study Part 2

    Complete response was defined as no vomiting and no use of rescue medication in 0-24 hours post-surgery.

    Time frame: Up to 24 Hours

  3. Number of Participants With No Vomiting Up to 48 Hours Following Surgery Ini Study Part 2

    Time frame: Up to 48 Hours

  4. Number of Participants With Complete Response Up to 48 Hours Following Surgery in Study Part 2

    Complete response was defined as no vomiting and no use of rescue medication in 0-48 hours post-surgery.

    Time frame: Up to 48 Hours

  5. Number of Participants With Vomiting Frequency in Study Part 2

    Time frame: Up to 24 Hours

07

Results

Posted Feb 14, 2014

Participant flow

This trial was conducted at 18 trial centers: 2 in Brazil, 1 in Finland, 1 in Russia, 1 in Mexico, 4 in Spain, 6 in Turkey, and 3 in the United States.

Participant flow — Overall Study
MilestonePart 1: Oral AprepitantPart 2: Oral AprepitantPart 2: Intravenous Ondansetron
Started462725
Completed442724
Not completed201
Withdrew: Physician decision101
Withdrew: Protocol violation100

Outcome measures

PrimaryArea Under the Curve From 0-48 (AUC0-48) of Aprepitant Following a Single Oral Dose in Study Part 1

Blood samples of 0.5 mL were collected from participants for the analysis of AUC0-48 at specified time points: pre-dose, and 1, 2, 3, 4, 8, 12, 24, and 48 hours post aprepitant single dose.

Time frame:
Pre-dose, and 1, 2, 3, 4, 8, 12, 24, and 48 hours post-dose
Reported as:
Mean · hr*ug/ml
Area Under the Curve From 0-48 (AUC0-48) of Aprepitant Following a Single Oral Dose in Study Part 1
hr*ug/mlPart 1: Oral Aprepitant
6 months to <2 years (n=11)5.97 ± 4.44
2 years to <6 years (n=11)4.76 ± 3.55
6 years to <12 years (n=11)6.16 ± 2.27
12 years to 17 years (n=10)6.01 ± 2.53
PrimaryMaximum Plasma Concentration (Cmax) of Aprepitant Following a Single Oral Dose in Study Part 1

Blood samples were collected from participants for the analysis of Cmax up to 48 hours after dosing.

Time frame:
48 Hours Post-Dose
Reported as:
Mean · ng/mL
Maximum Plasma Concentration (Cmax) of Aprepitant Following a Single Oral Dose in Study Part 1
ng/mLPart 1: Oral Aprepitant
6 months to <2 years (n=11)715 ± 445
2 years to <6 years (n=11)586 ± 462
6 years to <12 years (n=11)913 ± 294
12 years to 17 years (n=10)520 ± 230
PrimaryTime to Maximum Plasma Concentration (Tmax) of Aprepitant Following a Single Oral Dose in Study Part 1

Blood samples were collected from participants for the analysis of Tmax up to 48 hours after dosing.

Time frame:
48 Hours Post-Dose
Reported as:
Median · Hours
Time to Maximum Plasma Concentration (Tmax) of Aprepitant Following a Single Oral Dose in Study Part 1
HoursPart 1: Oral Aprepitant
6 months to <2 years (n=11)3.00 (1.00 to 8.00)
2 years to <6 years (n=11)3.00 (1.03 to 12.00)
6 years to <12 years (n=11)2.00 (1.00 to 8.00)
12 years to 17 years (n=10)3.50 (1.00 to 11.98)
PrimaryPlasma Concentration of Aprepitant at 24 Hours (C24 hr) Following a Single Oral Dose in Study Part 1

Blood samples were collected from participants for the analysis of C24 hr at 24 hours after dosing. N/A indicates that \>50% of measurements were below the lower level of quantitaion (LLOQ).

Time frame:
24 Hours Post-Dose
Reported as:
Mean · ng/mL
Plasma Concentration of Aprepitant at 24 Hours (C24 hr) Following a Single Oral Dose in Study Part 1
ng/mLPart 1: Oral Aprepitant
6 months to <2 years (n=11)31.0 ± 39.5
2 years to <6 years (n=11)58.6 ± 54.3
6 years to <12 years (n=11)51.1 ± 35.6
12 years to 17 years (n=10)81.1 ± 59.8
PrimaryPlasma Concentration of Aprepitant at 48 Hours (C48 hr) Following a Single Oral Dose in Study Part 1

The mean plasma concentration of aprepitant was evaluated in participants at 48 hours following a single oral dose.

Time frame:
48 Hours Post-Dose
Reported as:
Mean · ng/mL
Plasma Concentration of Aprepitant at 48 Hours (C48 hr) Following a Single Oral Dose in Study Part 1
ng/mLPart 1: Oral Aprepitant
6 months to <2 years (n=11)NA ± NA
2 years to <6 years (n=11)NA ± NA
6 years to <12 years (n=11)NA ± NA
12 years to 17 years (n=10)7.25 ± 8.90
PrimaryNumber of Participants Experiencing Adverse Events (AEs)
Time frame:
Up to 21 Days Post-Surgery
Reported as:
Number · Participants
Number of Participants Experiencing Adverse Events (AEs)
ParticipantsPart 1: Oral AprepitantPart 2: Oral AprepitantPart 2: Intravenous Ondansetron
Number of Participants Experiencing Adverse Events (AEs)20127
PrimaryNumber of Participants Discontinuing Study Treatment Due to AEs
Time frame:
Day 1
Reported as:
Number · Participants
Number of Participants Discontinuing Study Treatment Due to AEs
ParticipantsPart 1: Oral AprepitantPart 2: Oral AprepitantPart 2: Intravenous Ondansetron
Number of Participants Discontinuing Study Treatment Due to AEs000
SecondaryNumber of Participants With No Vomiting Up to 24 Hours Following Surgery in Study Part 2
Time frame:
Up to 24 Hours
Reported as:
Number · Participants
Number of Participants With No Vomiting Up to 24 Hours Following Surgery in Study Part 2
ParticipantsPart 2: Oral AprepitantPart 2: Intravenous Ondansetron
Number of Participants With No Vomiting Up to 24 Hours Following Surgery in Study Part 22020
SecondaryNumber of Participants With Complete Response Up to 24 Hours Following Surgery in Study Part 2

Complete response was defined as no vomiting and no use of rescue medication in 0-24 hours post-surgery.

Time frame:
Up to 24 Hours
Reported as:
Number · Participants
Number of Participants With Complete Response Up to 24 Hours Following Surgery in Study Part 2
ParticipantsPart 2: Oral AprepitantPart 2: Intravenous Ondansetron
Number of Participants With Complete Response Up to 24 Hours Following Surgery in Study Part 21920
SecondaryNumber of Participants With No Vomiting Up to 48 Hours Following Surgery Ini Study Part 2
Time frame:
Up to 48 Hours
Reported as:
Number · Participants
Number of Participants With No Vomiting Up to 48 Hours Following Surgery Ini Study Part 2
ParticipantsPart 2: Oral AprepitantPart 2: Intravenous Ondansetron
Number of Participants With No Vomiting Up to 48 Hours Following Surgery Ini Study Part 21820
SecondaryNumber of Participants With Complete Response Up to 48 Hours Following Surgery in Study Part 2

Complete response was defined as no vomiting and no use of rescue medication in 0-48 hours post-surgery.

Time frame:
Up to 48 Hours
Reported as:
Number · Participants
Number of Participants With Complete Response Up to 48 Hours Following Surgery in Study Part 2
ParticipantsPart 2: Oral AprepitantPart 2: Intravenous Ondansetron
Number of Participants With Complete Response Up to 48 Hours Following Surgery in Study Part 21720
SecondaryNumber of Participants With Vomiting Frequency in Study Part 2
Time frame:
Up to 24 Hours
Reported as:
Number · Participants
Number of Participants With Vomiting Frequency in Study Part 2
ParticipantsPart 2: Oral AprepitantPart 2: Intravenous Ondansetron
No Vomiting2020
1 Vomiting Episode53
2 Vomiting Episodes01
3 Vomiting Episodes00
>3 Vomiting Episodes01

Adverse events

Collected over Up to Day 21 post-surgery.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: Oral Aprepitant—3/46 (6.5%)14/46 (30.4%)
Part 2: Oral Aprepitant—2/27 (7.4%)5/27 (18.5%)
Part 2: Intravenous Ondansetron—0/25 (0%)4/25 (16%)
Most frequent serious events
Most frequent serious events
EventPart 1: Oral AprepitantPart 2: Oral AprepitantPart 2: Intravenous Ondansetron
Incision Site InfectionInfections and infestations2/461/270/25
PneumoniaInfections and infestations0/461/270/25
Anastomotic ComplicationInjury, poisoning and procedural complications1/460/270/25
Most frequent other events
Most frequent other events
EventPart 1: Oral AprepitantPart 2: Oral AprepitantPart 2: Intravenous Ondansetron
VomitingGastrointestinal disorders10/461/270/25
NauseaGastrointestinal disorders4/460/270/25
Chest PainGeneral disorders0/462/272/25
PyrexiaGeneral disorders3/460/272/25
Abdominal PainGastrointestinal disorders3/462/270/25

Baseline characteristics

Age, Customized
Age, Customized(Participants)Part 1: Oral AprepitantPart 2: Oral AprepitantPart 2: Intravenous OndansetronTotal
0.5 to <2 years148527
2 to <6 years117725
6 to <12 years115622
12 to 17 years107724
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: Oral AprepitantPart 2: Oral AprepitantPart 2: Intravenous OndansetronTotal
Female1361231
Male33211367
08

Study locations

6 sites
  • Call for Information (Investigational Site 0003)
    Louisville, Kentucky 40202, United States
  • Call for Information (Investigational Site 0022)
    Nashville, Tennessee 37232, United States
  • MSD
    Sao Paulo, SP 04717-004, Brazil
  • MSD
    Mexico City, 1090, Mexico
  • Merck Sharp and Dohme de Espana S.A.
    Madrid, 28027, Spain
  • Merck Sharp & Dohme Ilaclari Ltd. Sti
    Istanbul, Turkey
09

References and documents

Publications

  • Chain A, Wrishko R, Vasilinin G, Mouksassi S. Modeling and Simulation Analysis of Aprepitant Pharmacokinetics in Pediatric Patients With Postoperative or Chemotherapy-Induced Nausea and Vomiting. J Pediatr Pharmacol Ther. 2020;25(6):528-539. doi: 10.5863/1551-6776-25.6.528. PubMed 32839657 ↗

Individual participant data

Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2009 to primary completion in Mar 2013, 49 months.

Results were first posted in Feb 2014, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2009
First posted
Jan 8, 2009
StartActual
Jan 26, 2009
Primary completionActual
Mar 12, 2013
CompletionActual
Mar 12, 2013
Results first posted
Feb 14, 2014
Last update
Jan 26, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00819039
Responsible party
Sponsor
First posted
Jan 8, 2009
Start date
Jan 26, 2009
Primary completion
Mar 12, 2013
Completion
Mar 12, 2013
Results posted
Feb 14, 2014
Last update
Jan 26, 2021

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aprepitant

Start the discussion